DNA Damage Repair Germline Rare Variants as Predictors of Metastasis and Response to PARP Inhibitors
The intern will investigate whether normal DNA variants can cause prostate tumors to be more aggressive and to metastasize. If confirmed this mean the risk of metastasis could be predicted at diagnosis-even diagnosis at very early stage. Moreover, the intern will investigate whether the same DNA variants predict for effective FDA approved therapies that could be used very early before the cancer has metastasized. The partner will benefit from being introduced to the field of prostate cancer and the engineering of cancer genomes to model susceptibility and resistance to cancer therapeutics.